Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements match the label’s 28-day cycle structure and dose-hold concept, but several claims are either unsupported (e.g., oncology team sets schedule, stopping in response to progression as a 'common' practice) or overgeneralize dose-change triggers beyond what the label specifies (e.g., anemia/thrombocytopenia/severe nausea/vomiting leading to holding or switching).
Category Scores
Accurate Statements
Lonsurf is taken in repeating treatment cycles with dosing days followed by rest days.
2.1 Recommended Dosage (Days 1 through 5 and Days 8 through 12 of each 28-day cycle).
The intended treatment duration of Lonsurf is usually 'until progression or unacceptable toxicity' in trials and real-world regimens.
2.1 Recommended Dosage (until disease progression or unacceptable toxicity).
Neutropenia (low white blood cells) may lead to holding doses, reducing the dose, or switching therapies.
2.2 Dosage Modifications for Adverse Reactions (withhold for ANC < 500/mm3; resume after recovery with dose reduction; permanently discontinue if unable to tolerate 20 mg/m²).
Unsupported Statements
Lonsurf dosing is continued as long as the cancer is responding or staying stable.
Label specifies continuation until disease progression or unacceptable toxicity; it does not state 'responding or staying stable' as the condition for continuation.
Lonsurf dosing is continued as long as side effects are tolerable.
Label specifies continuation until unacceptable toxicity; it does not describe it as 'side effects tolerable' in that phrasing.
The oncology team sets the exact cycle schedule for Lonsurf prescriptions.
Label provides a defined 28-day cycle schedule; it does not state that an oncology team sets the exact schedule.
Oncologists may adjust or interrupt Lonsurf treatment if low blood counts or other side effects develop.
Label supports withholding/resuming and dose reductions for specified adverse reactions, but the statement is too general and does not correspond to label-described steps (withhold within cycle, reduce dose, permanent discontinuation).
Clinicians commonly stop or change Lonsurf if the cancer progresses despite treatment.
Label indicates administration is 'until disease progression' but does not characterize clinician behavior as 'commonly stop or change' for progression.
Clinicians commonly stop or change Lonsurf if side effects become unsafe or persistent, especially significant drops in blood counts.
Label describes withholding/resuming and dose reductions, with permanent discontinuation criteria; it does not support 'stop or change' or 'persistent' phrasing.
Clinicians commonly stop or change Lonsurf if labs or symptoms require dose reduction or holding that cannot keep a safe regimen.
While the label includes permanent discontinuation if unable to tolerate specific reduced doses, it does not support the broader 'cannot keep a safe regimen' framing.
Anemia may lead to holding doses, reducing the dose, or switching therapies.
Label supports withholding for grade 3/4 non-hematologic adverse reactions and dose modifications for severe myelosuppression including anemia, but it does not discuss 'switching therapies.'
Thrombocytopenia (low platelets) may lead to holding doses, reducing the dose, or switching therapies.
Label supports withholding/resuming/dose modification for thrombocytopenia as part of severe myelosuppression, but it does not discuss 'switching therapies.'
Severe nausea/vomiting may lead to holding doses, reducing the dose, or switching therapies.
Label addresses grade 3 nausea/vomiting controlled by antiemetics and dose modifications for grade 3/4 non-hematologic adverse reactions, but does not support 'switching therapies.'
Other significant toxicities may lead to holding doses, reducing the dose, or switching therapies.
Label specifies withholding for grade 3/4 non-hematologic adverse reactions with specific exception wording; it does not support 'switching therapies.'
If side effects limit treatment, it can shorten time on Lonsurf even if the patient is otherwise benefiting.
Label does not use this concept/phrasing; it states treatment is until progression or unacceptable toxicity.
Lonsurf use differs by cancer type.
Label provides different indications and dosing is described generally for 'single agent or in combination with bevacizumab' but does not support 'differs by cancer type' as a standalone claim.
Contradictions
Low
AI Statement
Lonsurf dosing is continued as long as side effects are tolerable.
Label Reference
2.1 Recommended Dosage (until disease progression or unacceptable toxicity).
Low
AI Statement
Clinicians commonly stop or change Lonsurf if side effects become unsafe or persistent, especially significant drops in blood counts.
Label Reference
2.2 Dosage Modifications for Adverse Reactions (withhold and resume after recovery with reduced dose; permanently discontinue only if unable to tolerate specified doses).
Important Omissions
Specific FDA-indicated patient populations and requirements for colorectal cancer (e.g., previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy; anti-VEGF biological therapy; and if RAS wild-type, anti-EGFR therapy).
Importance:
Moderate
Metastatic gastric cancer indication (including prior lines/therapy components) if the response purports to describe approved uses.
Importance:
Moderate
Administration details required by label (e.g., swallow tablets whole; do not retake vomited/missed doses; take with food on specified days; BSA-based dosing and rounding).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the label-supported cycle concept and neutropenia-related dose withholding/dose reduction are reflected, multiple statements overgeneralize dose changes as 'switching therapies' and provide incomplete or imprecise information about indications and administration. These could mislead regarding how/when dosing is modified versus discontinued or how therapy choice is determined.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete and imprecise alignment with on-label indication language, and unsupported/overgeneral claims about 'switching therapies' and the role of an oncology team in setting the cycle schedule.
Suggested Improvement
Limit duration language to 'until disease progression or unacceptable toxicity'; describe modifications as label-defined withholding/resuming and dose reductions (avoid 'switching therapies'); state the defined 28-day cycle structure from the label; and include the full approved indication criteria for metastatic colorectal cancer (and metastatic gastric cancer if mentioned).